Skip to content

An Investigation of Light Therapy for Cancer-related Fatigue (The LITE Study)

A Randomized Controlled Trial of Light Therapy on Biomarkers, Sleep/Wake Activity, and Quality of Life in Individuals With Post-treatment Cancer-related Fatigue

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01780623
Acronym
LITE
Enrollment
88
Registered
2013-01-31
Start date
2013-01-31
Completion date
2015-04-30
Last updated
2016-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

fatigue, sleep, quality of life, light, cancer

Brief summary

Cancer-related fatigue is one of the most common and distressing symptoms associated with a cancer diagnosis.Fatigue related to cancer often appears before a diagnosis, worsens during treatment, and lasts for years after treatment in up to 35% of patients. Despite the long-term effects of cancer-related fatigue, the treatment options available are not always appropriate or helpful for all patients.Light therapy is an effective treatment for other disorders related to fatigue. The purpose of the study is to investigate the role of light therapy on quality of life, sleep patterns, and physical measures of immune function and stress hormones in individuals with post-treatment cancer-related fatigue.

Interventions

Sponsors

Canadian Cancer Society (CCS)
CollaboratorOTHER
University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* English speaking * Non metastatic cancer * At least 3 months post chemotherapy/radiation treatment (hormone treatment ok) * Meets criteria for cancer-related fatigue

Exclusion criteria

* Under 18 years of age * Presence of a sleep disorder other than insomnia or hypersomnia * Shift work * Presence of an Axis-I psychiatric condition * Presence of a medical condition that may impact levels of fatigue * Presence of conditions contraindicated to the use of light therapy or photosensitizing medications * Randomization refusal

Design outcomes

Primary

MeasureTime frame
Change in fatigue symptoms from baseline to post-treatmentBaseline, after each treatment week (each week for 4 weeks), and at week 5

Secondary

MeasureTime frame
Change in subjective measures of sleep using sleep diaries from baseline to post-treatmentBaseline (for 7 days), week 5 (for 7 days)
Change in Pittsburgh Sleep Quality Index scores from baseline to post-treatmentBaseline, week 5
Change in Profile of Mood States scores from baseline to post-treatmentBaseline, week 5
Change in objective measures of sleep using wrist actigraphy from baseline to post-treatmentBaseline (for 7 days), week 5 (for 7 days)
Change in salivary cortisol from baseline to post-treatmentBaseline (for 3 days), week 5 (for 3 days)
Change in inflammatory cytokines from baseline to post-treatmentBaseline, week 5
Change in Insomnia Severity Index scores from baseline to post-treatmentBaseline, week 3, week 5
Change in Functional Assessment of Cancer Therapy (General & Fatigue) scores from baseline to post-treatmentBaseline, week 5

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026